Sugi Predict

Sugi Predict / Compounds / SCHEMBL800204

SCHEMBL800204

SCHEMBL800204

C[C@H](O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 1/20 0.64
▸ WDR77 Q9BQA1 1/20 0.64
▸ AHCY P23526 8/20 0.64
▸ ADORA2B P29275 4/20 0.64
▸ ADORA3 P0DMS8 3/20 0.64
▸ ADORA2A P29274 3/20 0.64
▸ KMT2A Q03164 2/20 0.64
▸ ADORA1 P30542 2/20 0.64
▸ HSP90B1 P14625 2/20 0.64
▸ TSHR P16473 1/20 0.64
▸ LMNA P02545 1/20 0.64
▸ THRB P10828 1/20 0.64
▸ BLM P54132 1/20 0.64
▸ HSP90AA1 P07900 1/20 0.64
▸ DOT1L Q8TEK3 2/20 0.63
▸ DPP4 P27487 1/20 0.63
▸ MEN1 O00255 1/20 0.63
▸ SLC28A1 O00337 1/20 0.63
▸ MAP3K7 O43318 1/20 0.63
▸ SLC28A2 O43868 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270819 1.00 PRMT5 (0.64) PRMT5WDR77AHCYADORA2BADORA3
SCHEMBL800381 1.00 PRMT5 (0.64) PRMT5WDR77AHCYADORA2BADORA3
SCHEMBL13134675 1.00 PRMT5 (0.64) PRMT5WDR77AHCYADORA2BADORA3
SCHEMBL13173634 1.00 PRMT5 (0.64) PRMT5WDR77AHCYADORA2BADORA3
SCHEMBL18520788 1.00 PRMT5 (0.64) PRMT5WDR77AHCYADORA2BADORA3
SCHEMBL16300875 1.00 PRMT5 (0.64) PRMT5WDR77AHCYADORA2BADORA3
SCHEMBL800346 1.00 PRMT5 (0.64) PRMT5WDR77AHCYADORA2BADORA3
SCHEMBL21413837 1.00 PRMT5 (0.64) PRMT5WDR77AHCYADORA2BADORA3
SCHEMBL22326787 1.00 PRMT5 (0.64) PRMT5WDR77AHCYADORA2BADORA3
SCHEMBL22326785 1.00 PRMT5 (0.64) PRMT5WDR77AHCYADORA2BADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3344644-B1 CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS MERCK SHARP & DOHME LLC (US) 2024-06-26 — — EP disclosed
US-10738074-B2 Cyclic di-nucleotide compounds as STING agonists MERCK SHARP & DOHME CORP. (US) 2020-08-11 — — US disclosed
EP-3262057-B1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER (US) 2020-04-15 — — EP disclosed
US-10428104-B2 Substituted nucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2019-10-01 — — US disclosed
US-10428104-B2 Substituted nucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2019-10-01 — — US disclosed
EP-2655392-B1 CYCLIC NUCLEOTIDE ANALOGS ALIOS BIOPHARMA INC (US) 2018-04-18 — — EP disclosed
EP-3262057-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Inc (US) 2018-01-03 — — EP disclosed
WO-2016135582-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2016-09-01 — — WO disclosed
WO-2016135582-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2016-09-01 — — WO disclosed
US-20160244475-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2016-08-25 — — US disclosed
US-8772474-B2 Cyclic nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2014-07-08 — — US disclosed
US-8772474-B2 Cyclic nucleotide analogs ALIOS BIOPHARMA, INC. (US) 2014-07-08 — — US disclosed
US-20120165286-A1 CYCLIC NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-06-28 — — US disclosed
US-20120165286-A1 CYCLIC NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-06-28 — — US disclosed
WO-2012088155-A1 CYCLIC NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-06-28 — — WO disclosed
WO-2012040126-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-29 — — WO disclosed
US-20120070411-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-22 — — US disclosed
US-20120070411-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-22 — — US disclosed
US-20100249068-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-30 — — US disclosed
US-20100249068-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428104-B2 Substituted nucleoside derivatives useful as anticancer agents TYMP, NME1, DPYD PRMT5 1543/4885WDR77 2428/4885AHCY 2087/4885
US-20160244475-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS TYMP, NME1, PNP PRMT5 1552/4885WDR77 2124/4885AHCY 3185/4885
US-10738074-B2 Cyclic di-nucleotide compounds as STING agonists STING1, CGAS, IFNAR1 PRMT5 4069/4885WDR77 2727/4885AHCY 4801/4885
US-20120070411-A1 SUBSTITUTED NUCLEOTIDE ANALOGS PNP, NTPCR, NUDT1 PRMT5 3112/4885WDR77 1331/4885AHCY 293/4885
US-20100249068-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS PNP, TYMP, NTPCR PRMT5 4037/4885WDR77 1883/4885AHCY 964/4885
US-20120165286-A1 CYCLIC NUCLEOTIDE ANALOGS NT5C2, NTPCR, PNP PRMT5 3305/4885WDR77 2470/4885AHCY 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.